# EDGAR Filing Document

**Accession Number:** 0001736225
**File Stem:** 0000905148-25-004126
**Filing Date:** 2025-11
**Character Count:** 14287
**Document Hash:** d2d14228517de8ae95b0be3c3f10dce8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000905148-25-004126.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0000905148-25-004126

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Keros Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001664710
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811173868
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91484
- **FILM NUMBER:** 251494668

**BUSINESS ADDRESS:**
- **STREET 1:** 1050 WALTHAM STREET, SUITE 302
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
- **BUSINESS PHONE:** 617-314-6297

**MAIL ADDRESS:**
- **STREET 1:** 1050 WALTHAM STREET, SUITE 302
- **CITY:** LEXINGTON
- **STATE:** MA
- **ZIP:** 02421
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ExodusPoint Capital Management, LP
- **CENTRAL INDEX KEY:** 0001736225

**ORGANIZATION NAME:**
- **EIN:** 371875900
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 65 E 55TH STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 6469409426

**MAIL ADDRESS:**
- **STREET 1:** 65 E 55TH STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

## Ex-1

#### EXHIBIT 1

#### JOINT FILING AGREEMENT

#### PURSUANT TO RULE 13d-1(k)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: November 18, 2025

---

| | |
|:---|:---|
| **ExodusPoint Capital Management, LP** | **ExodusPoint Capital Management, LP** |
| By: | /s/ Timothy Cruise |
| Name: | Timothy Cruise |
| Title: | Authorized Signatory |
| **ExodusPoint Capital Partners GP, LLC** | **ExodusPoint Capital Partners GP, LLC** |
| By: | /s/ Timothy Cruise |
| Name: | Timothy Cruise |
| Title: | Authorized Signatory |
| **Michael Gelband** | **Michael Gelband** |
| By: | /s/ Michael Gelband |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** Keros Therapeutics, Inc.

**Title of Class of Securities:** Common Stock, $0.0001 par value per share

**CUSIP Number:** 492327101

**Date of Event Which Requires Filing of this Statement:** 11/10/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>ExodusPoint Capital Management, LP | Names of Reporting Persons<br>ExodusPoint Capital Management, LP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1907899 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1907899 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.3% | Percent of Class Represented by Amount in Row (9)<br>6.3% |
| 12. | Type of Reporting Person (See Instructions)<br>IA, PN | Type of Reporting Person (See Instructions)<br>IA, PN |

---

| 1. | Names of Reporting Persons<br>ExodusPoint Capital Partners GP, LLC | Names of Reporting Persons<br>ExodusPoint Capital Partners GP, LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1907899 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1907899 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.3% | Percent of Class Represented by Amount in Row (9)<br>6.3% |
| 12. | Type of Reporting Person (See Instructions)<br>CO, HC | Type of Reporting Person (See Instructions)<br>CO, HC |

---

| 1. | Names of Reporting Persons<br>Michael Gelband | Names of Reporting Persons<br>Michael Gelband |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>1907899 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>1907899 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>1907899 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>6.3% | Percent of Class Represented by Amount in Row (9)<br>6.3% |
| 12. | Type of Reporting Person (See Instructions)<br>IN, HC | Type of Reporting Person (See Instructions)<br>IN, HC |

---

**Item 1(a). Name of Issuer:**
Keros Therapeutics, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
1050 Waltham Street, Suite 302, Lexington, Massachusetts, 02421

**Item 2(a). Name of Person Filing:**
This statement is filed by (each, a "Reporting Person" and, collectively, the "Reporting Persons"): (i) ExodusPoint Capital Management, LP ("ExodusPoint Capital Management") with respect to shares of Common Stock, $0.0001 par value per share ("Shares") of the Issuer held by ExodusPoint Partners Master Fund, LP, an investment fund it manages ("ExodusPoint Master Fund"); (ii) ExodusPoint Capital Partners GP, LLC ("ExodusPoint Capital Partners") with respect to Shares held by ExodusPoint Master Fund; and (iii) Michael Gelband ("Mr. Gelband"), with respect to Shares beneficially owned by ExodusPoint Capital Management and ExodusPoint Capital Partners.

ExodusPoint Capital Management, ExodusPoint Capital Partners, and Mr. Gelband have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of ExodusPoint Capital Management, ExodusPoint Capital Partners, and Mr. Gelband is 65 East 55th Street, New York, NY 10022.

**Item 2(c). Citizenship:**
ExodusPoint Capital Management is a Delaware limited partnership. ExodusPoint Capital Partners is a Delaware limited liability company. Mr. Gelband is a United States citizen.

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**Item 2(e). CUSIP Number:**
492327101

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

As of November 17, 2025, each of the Reporting Persons may be deemed the beneficial owner of 1,907,899 Shares, which are held directly by ExodusPoint Master Fund.
ExodusPoint Capital Management, ExodusPoint Capital Partners, and Mr. Gelband directly own no Shares. Pursuant to an investment management agreement, ExodusPoint Capital Management maintains investment and voting power with respect to the securities held by ExodusPoint Master Fund. ExodusPoint Capital Partners is the general partner of ExodusPoint Capital Management. Mr. Gelband controls each of ExodusPoint Capital Management and ExodusPoint Capital Partners.

**(b) Percent of class:**

As of November 17, 2025, each of the Reporting Persons may be deemed to beneficially own approximately 6.3% of the Shares outstanding.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0.00

**(ii) Shared power to vote or to direct the vote:**

1,907,899.00

**(iii) Sole power to dispose or to direct the disposition of:**

0.00

**(iv) Shared power to dispose or to direct the disposition of:**

1,907,899.00

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

ExodusPoint Master Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

**Item 7. Identification and Classification of the Subsidiary**

See disclosure in Item 4 hereof.

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**ExodusPoint Capital Management, LP**

**Date:** 11/18/2025

**By:** /s/ Timothy Cruise

**Name & Title:** Timothy Cruise, Authorized Signatory

**ExodusPoint Capital Partners GP, LLC**

**Date:** 11/18/2025

**By:** /s/ Timothy Cruise

**Name & Title:** Timothy Cruise, Authorized Signatory

**Michael Gelband**

**Date:** 11/18/2025

**By:** /s/ Michael Gelband

**Name & Title:** Michael Gelband